Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer

Inclusion Criteria: * Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated * Has a Prostate-specific Antigen (PSA) level ≥2.0 ng/mL at Screening * Has a screening serum testosterone level \>150 ng/dL * Has an Eastern Cooperative Oncology Group (ECOG) score of ≤2 Exclusion Criteria: * Has had previous or is currently under hormonal management of prostate cancer. However, hormonal therapy for a maximum duration of 6 months is accepted. This treatment should have been terminated at least 6 months prior to the Screening Visit * Is currently treated with a 5-alpha reductase inhibitor * Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy * Is in need of neoadjuvant hormonal therapy * Has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy